Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

328 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease.
Lindholm D, Lindbäck J, Armstrong PW, Budaj A, Cannon CP, Granger CB, Hagström E, Held C, Koenig W, Östlund O, Stewart RAH, Soffer J, White HD, de Winter RJ, Steg PG, Siegbahn A, Kleber ME, Dressel A, Grammer TB, März W, Wallentin L. Lindholm D, et al. Among authors: budaj a. J Am Coll Cardiol. 2017 Aug 15;70(7):813-826. doi: 10.1016/j.jacc.2017.06.030. J Am Coll Cardiol. 2017. PMID: 28797349 Free article. Clinical Trial.
Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE).
Steg PG, Dabbous OH, Feldman LJ, Cohen-Solal A, Aumont MC, López-Sendón J, Budaj A, Goldberg RJ, Klein W, Anderson FA Jr; Global Registry of Acute Coronary Events Investigators. Steg PG, et al. Among authors: budaj a. Circulation. 2004 Feb 3;109(4):494-9. doi: 10.1161/01.CIR.0000109691.16944.DA. Epub 2004 Jan 26. Circulation. 2004. PMID: 14744970
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
MICHELANGELO OASIS 5 Steering Committee; Mehta SR, Yusuf S, Granger CB, Wallentin L, Peters RJ, Bassand JP, Budaj A, Joyner C, Chrolavicius S, Fox KA. MICHELANGELO OASIS 5 Steering Committee, et al. Among authors: budaj a. Am Heart J. 2005 Dec;150(6):1107. doi: 10.1016/j.ahj.2005.09.025. Am Heart J. 2005. PMID: 16338245 Clinical Trial.
The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE).
Goodman SG, Steg PG, Eagle KA, Fox KA, López-Sendón J, Montalescot G, Budaj A, Kennelly BM, Gore JM, Allegrone J, Granger CB, Gurfinkel EP; GRACE Investigators. Goodman SG, et al. Among authors: budaj a. Am Heart J. 2006 Mar;151(3):654-60. doi: 10.1016/j.ahj.2005.05.014. Am Heart J. 2006. PMID: 16504627
Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators; Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, et al. Among authors: budaj a. N Engl J Med. 2006 Apr 6;354(14):1464-76. doi: 10.1056/NEJMoa055443. Epub 2006 Mar 14. N Engl J Med. 2006. PMID: 16537663 Free article. Clinical Trial.
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA; OASIS-6 Trial Group. Yusuf S, et al. Among authors: budaj a. JAMA. 2006 Apr 5;295(13):1519-30. doi: 10.1001/jama.295.13.joc60038. Epub 2006 Mar 14. JAMA. 2006. PMID: 16537725 Clinical Trial.
328 results